Working… Menu

A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy (LAPAINBLAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01245660
Recruitment Status : Terminated (The rythm of enrollment was not compatible with the objective of recruitement in the research.)
First Posted : November 22, 2010
Last Update Posted : January 11, 2013
Information provided by (Responsible Party):
University Hospital, Bordeaux

Brief Summary:
Modification of the EGF signalling pathway and / or HER 2, by Lapatinib in bladder cancer.

Condition or disease Intervention/treatment Phase
Bladder Carcinoma Infiltrative Bladder Carcinoma Cystectomy Drug: LAPATINIB Early Phase 1

Detailed Description:

Patients with invasive bladder tumor , candidates for radical cystectomy. Patients will receive Lapatinib during 3 weeks +/- 5 days, before cystectomy. A comparison of tissue from the original biopsy and cystectomy after Lapatinib will allow this to occur.

TREATMENT AND STRATEGY Lapatinib in bladder carcinoma -Overall there are arguments for considering that egf pathway is involved in bladder carcinoma and so far that drugs inhibiting EGF pathway could have an impact for therapeutical endpoints.

Nevertheless it is unclear that from previous studies that adding egf inhibiting drug to chemotherapy is clinically relevant, essentially by difficulties to measure a beneficial endpoint while downstream EGF pathways have been modified by these drugs, as shown with lapatinib (see 2.1.5).

Furthermore, there is no argument for initial selection of patients based on the initial egfr and/or her 2 tumor profile, asking for more intense knowledge.

LAPATINIB TREATMENT Patients will receive lapatinib therapy at a daily standard dose of 1500 mg.

LAPATINIB TREATMENT DURATION Patients will then receive 3 weeks of lapatinib therapy + possible 5 days. As the study is a non direct benefit study, the exposition to the drug is proposed during the standard window of 3 to 4 weeks to organize a radical cystectomy in patients with muscle invasive bladder carcinoma. In this study patients, the standard procedure is not delayed for the purpose of the study.

The duration of exposition to lapatinib as to be long enough to have a continuous impact of biological events to induce indeed inhibition of EGF pathway but also to impact on more complex or more distal events as apoptosis and so to be able to measure it. This justifies a 3 weeks of treatment + possible up to 5 days more due to surgical organization procedures.

Surgery will take place on the last day of treatment, which is recommended due to the half-life of lapatinib. Nevertheless for surgical purpose, the drug could be not given on the day of surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Pilot Study of Lapatinib (Tyverb®) in Neoadjuvant Treatment for Patients With Locally Bladder Carcinoma Before Cystectomy
Study Start Date : January 2011
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer

Arm Intervention/treatment
Experimental: Patient Drug: LAPATINIB
Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.

Primary Outcome Measures :
  1. Effect on egf pathway at a molecular level of 3 weeks treatment by lapatinib. [ Time Frame: At surgery (day 21-27) ]
    The primary objective of the study is to evaluate the effect at a molecular level, of 3 weeks of neoadjuvant lapatinib, in locally advanced muscle-invasive transitional cell carcinoma of the bladder. A comparison of tissue from the original biopsy and cystectomy after lapatinib will allow this to occur. This effect will be evaluated by studying proliferation and apoptotic markers as well as the phosphorylation of proteins which are components of the egf signalling pathway.

Secondary Outcome Measures :
  1. Lapatinib biological response on key molecules of the egf pathway (EGFR, ERBB2, AKT ERK as well as their phosphorylation status.) [ Time Frame: At screening (day -10 before inclusion) , surgery (day 21-27) and Follow up visit surgery (day 42-62) ]
    Because the availability of large scale data, the correlation between lapatinib biological response and the molecular alteration of other molecules beside those involved in the egf pathway will be explored. i.e. key molecules of the pathway will also be studied at the protein level (EGFR, ERBB2, AKT ERK) as well as their phosphorylation status.

  2. Histological response [ Time Frame: At surgery (day 21-27) ]
    To evaluate the histological response to lapatinib at the time of surgery

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must sign and date IRB/EC-approved informed consent,
  • Age ≥ 18
  • Patients must have a life expectancy of at least 6 months,
  • Patients must have a Karnofsky performance status ≥ 80%,
  • Clinical stage T2NxM0 to T4aNxM0 bladder cancer
  • Muscle-invasive transitional cell carcinoma by histology (focal squamous and/or adenocarcinoma differentiation defined as ≤ 10% of tumor volume allowed, sarcomatoid and small-cell components not allowed)
  • Considered to have a macroscopic residue in the bladder to allow comparison of tissue samples at cystectomy to initial biopsies
  • Candidates for radical cystectomy
  • Patient with normal cardiac function, LVEF ≥ 50% measured by echocardiography or MUGA scan
  • Able to swallow and retain oral medication
  • A female is eligible to enter and participate in this study if she is of : Non-child-bearing potential (i.e., a woman with functioning ovaries who have a current documented tubal ligation or hysterectomy or a woman who is menopausal), or Child-bearing potential (i.e. a woman with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility. This category includes women with oligomenorrhoea (even severe), women who are perimenopausal and young women who have begun to menstruate), who have a negative serum pregnancy test at screening, and agree to one of the following consistent and correct use of one acceptable methods of birth control : Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, or combined oral contraception
  • care must be taken to avoid pregnancy in partners of male patients.
  • Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
  • Affiliated or profit patient of a social security system

Exclusion Criteria:

  • Prior pelvic radiation or neoadjuvant chemotherapy.
  • Pregnancy or breastfeeding.
  • Other severe acute or chronic medical or psychiatric condition that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
  • Patients with significantly reduced LVEF or LVEF < 50%.
  • Patient with any of the following liver abnormal laboratory test :
  • Serum bilirubin > 1,5 x upper limit of normal (ULN) (in case of Gilbert syndrome, a higher serum total bilirubin (< 2 ULN) is allowed
  • Alanine amino transferase (ALAT) or aspartate amino transferase (ASAT) > 2,5 ULN
  • Platelets <100 x 109/L, hemoglobin < 9 g/dl, absolute neutrophil count (ANC) <1.5 x 109/L
  • Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  • Serum creatinine > 1.5 x ULN.
  • Previous therapy targeting EGFR or HER-2.
  • Predominantly non transitional cell histology.
  • Diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma of the cervix uteri that has been adequately treated with no evidence of recurrent disease for 12 months.
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, or major resection of the stomach or bowel, that could affect absorption of lapatinib.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, that would limit compliance with study requirements.
  • History of uncontrolled or symptomatic angina
  • History of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation
  • Myocardial infarction < 6 months from study entry
  • Uncontrolled or symptomatic congestive heart failure
  • Ejection fraction below the institutional normal limit
  • Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
  • Use of an investigational agent within 30 days or 5 half-lives, whichever is the longer, preceding the first dose of investigational product.
  • Concurrent treatment with an investigational agent
  • Concurrent treatment with cytotoxic chemotherapy, immunotherapy, biologic therapy, hormonal therapy or curative radiotherapy for locally advanced or metastatic TCC of the urothelial tract.
  • Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.
  • Patient under safeguard of justice

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01245660

Layout table for location information
CHU Bordeaux - Hôpital Saint André - Department of Medical Oncology
Bordeaux, France, 33075
Sponsors and Collaborators
University Hospital, Bordeaux
Layout table for investigator information
Study Chair: Geneviève CHENE, Pr USMR Bordeaux
Layout table for additonal information
Responsible Party: University Hospital, Bordeaux Identifier: NCT01245660    
Other Study ID Numbers: CHUBX 2009/04
First Posted: November 22, 2010    Key Record Dates
Last Update Posted: January 11, 2013
Last Verified: January 2013
Keywords provided by University Hospital, Bordeaux:
Phase 0
Bladder carcinoma
egf pathway
infiltrative bladder carcinoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urologic Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action